TR200101938T2 - Pde-ıv inhibe edici aktivitesi olan fenilfenantridinler. - Google Patents

Pde-ıv inhibe edici aktivitesi olan fenilfenantridinler.

Info

Publication number
TR200101938T2
TR200101938T2 TR2001/01938T TR200101938T TR200101938T2 TR 200101938 T2 TR200101938 T2 TR 200101938T2 TR 2001/01938 T TR2001/01938 T TR 2001/01938T TR 200101938 T TR200101938 T TR 200101938T TR 200101938 T2 TR200101938 T2 TR 200101938T2
Authority
TR
Turkey
Prior art keywords
phenylphenanthridines
pde
inhibitory activity
formula
bronsial
Prior art date
Application number
TR2001/01938T
Other languages
English (en)
Turkish (tr)
Inventor
Gutterer Beate
Flockerzi Dieter
Amschler Hermann (Merhum)
Grundler Gerhard
Hatzelmann Armin
Bundschuh Daniela
Beume Rolf
Boss Hildegard
Kley Hans-Peter
Original Assignee
Byk Gulden Lomberg Chemische Fabrik Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chemische Fabrik Gmbh filed Critical Byk Gulden Lomberg Chemische Fabrik Gmbh
Publication of TR200101938T2 publication Critical patent/TR200101938T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
TR2001/01938T 1999-01-15 2000-01-12 Pde-ıv inhibe edici aktivitesi olan fenilfenantridinler. TR200101938T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99100694 1999-01-15

Publications (1)

Publication Number Publication Date
TR200101938T2 true TR200101938T2 (tr) 2001-12-21

Family

ID=8237351

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2005/01553T TR200501553T2 (tr) 1999-01-15 2000-01-12 PDE-IV inhibe edici aktivitesi olan fenilfenantridinler
TR2001/01938T TR200101938T2 (tr) 1999-01-15 2000-01-12 Pde-ıv inhibe edici aktivitesi olan fenilfenantridinler.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2005/01553T TR200501553T2 (tr) 1999-01-15 2000-01-12 PDE-IV inhibe edici aktivitesi olan fenilfenantridinler

Country Status (32)

Country Link
US (1) US6476025B1 (enExample)
EP (2) EP1650193A3 (enExample)
JP (1) JP4653314B2 (enExample)
KR (1) KR100720906B1 (enExample)
CN (1) CN1152864C (enExample)
AT (1) ATE312081T1 (enExample)
AU (1) AU774868B2 (enExample)
BG (1) BG65126B1 (enExample)
BR (1) BR0007527B1 (enExample)
CA (1) CA2359440C (enExample)
CY (1) CY1106436T1 (enExample)
CZ (1) CZ300366B6 (enExample)
DE (1) DE60024581T2 (enExample)
DK (1) DK1147089T3 (enExample)
EA (1) EA003780B1 (enExample)
EE (1) EE05105B1 (enExample)
ES (1) ES2254132T3 (enExample)
HK (1) HK1040997B (enExample)
HR (1) HRP20010578A2 (enExample)
HU (1) HU227624B1 (enExample)
ID (1) ID29070A (enExample)
IL (2) IL144026A0 (enExample)
NO (1) NO320182B1 (enExample)
NZ (1) NZ512872A (enExample)
PL (1) PL205670B1 (enExample)
RS (1) RS50297B (enExample)
SI (1) SI1147089T1 (enExample)
SK (1) SK286946B6 (enExample)
TR (2) TR200501553T2 (enExample)
UA (1) UA69436C2 (enExample)
WO (1) WO2000042020A1 (enExample)
ZA (1) ZA200104864B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006238A1 (en) * 2000-07-14 2002-01-24 Altana Pharma Ag Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
WO2004018431A2 (en) * 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
DE60311662T2 (de) * 2002-08-29 2007-10-25 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
CA2495827C (en) 2002-08-29 2012-05-08 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides
WO2005012253A1 (en) * 2003-07-31 2005-02-10 Altana Pharma Ag Novel 6-phenylphenanthridines
US20060189645A1 (en) * 2003-07-31 2006-08-24 Altana Pharma Ag Novel 6-phenylphenantridines
WO2005023253A1 (en) * 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
EP1720835B1 (en) 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
AR049419A1 (es) * 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
PT2589599E (pt) 2004-03-03 2014-09-02 Takeda Gmbh Novas hidroxi-6-heteroarilfenantridinas e sua utilização como inibidores de pde4
US20070191414A1 (en) * 2004-03-09 2007-08-16 Altana Pharma Ag Novel isoamido-substituted hydroxy-6-phenylphenanthridines
AU2005219581A1 (en) * 2004-03-10 2005-09-15 Nycomed Gmbh Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
AU2005221832A1 (en) * 2004-03-10 2005-09-22 Nycomed Gmbh Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
WO2005087744A1 (en) * 2004-03-10 2005-09-22 Altana Pharma Ag Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
EP1791847A2 (en) * 2004-09-08 2007-06-06 Altana Pharma AG Novel 3-thia-10-aza-phenanthrene derivatives
US7411093B2 (en) * 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
KR101352687B1 (ko) * 2005-03-02 2014-02-17 다케다 게엠베하 6-헤테로시클릴 치환된 헥사히드로페난트리딘 유도체의신규한 염
US8017633B2 (en) 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
JP2008532980A (ja) * 2005-03-09 2008-08-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング アミド置換された６−フェニルフェナントリジン
EP2207540B1 (en) 2007-10-04 2014-02-26 F. Hoffmann-La Roche AG Cyclopropyl aryl amide derivatives and uses thereof
WO2013096744A1 (en) 2011-12-21 2013-06-27 Novira Therapeutics, Inc. Hepatitis b antiviral agents
AU2013307331A1 (en) 2012-08-28 2015-02-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B
PT2961732T (pt) 2013-02-28 2017-06-26 Janssen Sciences Ireland Uc Sulfamoil-arilamidas e utilização das mesmas como medicamentos para o tratamento de hepatite b
EA027068B1 (ru) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
CN105960400B (zh) 2013-05-17 2019-05-31 爱尔兰詹森科学公司 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
AU2014294997B2 (en) 2013-07-25 2018-03-22 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US20150216938A1 (en) 2014-02-05 2015-08-06 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
UY35980A (es) 2014-02-06 2015-08-31 Janssen Sciences Ireland Uc Derivados de sulfamoilpirrolamida como inhibidores del hbv y composiciones farmacéuticas que los contienen
CA2980298A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10077239B2 (en) 2015-09-29 2018-09-18 Novira Therapeutics, Inc. Crystalline forms of a hepatitis B antiviral agent
MA44671A (fr) 2016-04-15 2019-02-20 Janssen Sciences Ireland Uc Associations et méthodes comprenant un inhibiteur d'ensemble capside
EA202092171A1 (ru) 2018-03-14 2020-12-01 Янссен Сайенсиз Айрлэнд Анлимитед Компани Схема дозирования модулятора сборки капсида
KR20210130753A (ko) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체
MA55879A (fr) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899494A (en) * 1970-05-13 1975-08-12 Sandoz Ltd Substituted 6-phenyl benzo-naphthyridines
PT882021E (pt) * 1996-01-31 2003-07-31 Altana Pharma Ag Novas fenantridinas
JP4141501B2 (ja) * 1996-03-26 2008-08-27 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の６位置換フェナントリジン
US6127378A (en) 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
PL189641B1 (pl) 1996-11-11 2005-09-30 Altana Pharma Ag Benzonaftyrydyny, środki farmaceutyczne je zawierające oraz zastosowanie benzonaftyrydyn
ES2206909T3 (es) 1997-03-07 2004-05-16 Altana Pharma Ag Derivados de tetrazol.
WO1998055481A1 (en) 1997-06-03 1998-12-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine
HUP0003311A3 (en) * 1997-07-25 2002-10-28 Altana Pharma Ag Substituted 6-phenylphenanthridine derivatives, pocess for producing them and pharmaceutical compositions containing them
ATE260899T1 (de) 1997-07-25 2004-03-15 Altana Pharma Ag Neue tetrazolderivate
AU2107700A (en) * 1999-01-15 2000-08-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridine-n-oxides with pde-iv inhibiting activity
EP1147088B1 (en) * 1999-01-15 2006-01-04 ALTANA Pharma AG 6-arylphenanthridines with pde-iv inhibiting activity
DK1147103T3 (da) * 1999-01-15 2005-08-29 Altana Pharma Ag Phenanthridin-N-oxider med PDE-IV-inhiberende aktivitet

Also Published As

Publication number Publication date
NO20013341D0 (no) 2001-07-05
AU774868B2 (en) 2004-07-08
HU227624B1 (en) 2011-09-28
NO20013341L (no) 2001-09-17
HK1040997A1 (en) 2002-06-28
EP1650193A3 (en) 2006-10-04
NZ512872A (en) 2003-07-25
ZA200104864B (en) 2003-04-15
ES2254132T3 (es) 2006-06-16
HUP0105001A3 (en) 2002-10-28
RS50297B (sr) 2009-09-08
JP4653314B2 (ja) 2011-03-16
CA2359440A1 (en) 2000-07-20
EE200100350A (et) 2002-10-15
KR100720906B1 (ko) 2007-05-25
EP1650193A2 (en) 2006-04-26
SI1147089T1 (sl) 2006-04-30
SK286946B6 (sk) 2009-08-06
BR0007527A (pt) 2001-12-04
CN1152864C (zh) 2004-06-09
NO320182B1 (no) 2005-11-07
EE05105B1 (et) 2008-12-15
KR20010086164A (ko) 2001-09-08
DE60024581T2 (de) 2006-08-10
PL348925A1 (en) 2002-06-17
TR200501553T2 (tr) 2005-06-21
EA200100731A1 (ru) 2002-02-28
SK9802001A3 (en) 2001-12-03
PL205670B1 (pl) 2010-05-31
CA2359440C (en) 2009-04-14
UA69436C2 (uk) 2004-09-15
ATE312081T1 (de) 2005-12-15
CY1106436T1 (el) 2011-10-12
BR0007527B1 (pt) 2011-12-27
US6476025B1 (en) 2002-11-05
EP1147089B1 (en) 2005-12-07
YU48701A (sh) 2004-05-12
BG65126B1 (bg) 2007-03-30
AU2289600A (en) 2000-08-01
HUP0105001A2 (hu) 2002-04-29
DE60024581D1 (de) 2006-01-12
WO2000042020A1 (en) 2000-07-20
HRP20010578A2 (en) 2002-08-31
CZ300366B6 (cs) 2009-05-06
DK1147089T3 (da) 2006-04-10
JP2002534508A (ja) 2002-10-15
CN1336919A (zh) 2002-02-20
HK1040997B (en) 2006-07-14
BG105561A (en) 2001-12-29
IL144026A (en) 2007-05-15
EA003780B1 (ru) 2003-08-28
ID29070A (id) 2001-07-26
EP1147089A1 (en) 2001-10-24
IL144026A0 (en) 2002-04-21
CZ20012248A3 (cs) 2001-09-12

Similar Documents

Publication Publication Date Title
TR200101938T2 (tr) Pde-ıv inhibe edici aktivitesi olan fenilfenantridinler.
DK0882021T3 (da) Nye phenanthridiner
TR200100672T2 (tr) Yeni izoksazolinon antibakteriyel ajanları
ATE258930T1 (de) Dihydrobenzifurane
DK1147103T3 (da) Phenanthridin-N-oxider med PDE-IV-inhiberende aktivitet
TR200101779T2 (tr) Yeni bisiklik bileşenler
DK1109810T3 (da) Benzonaphthydin-N-oxider med PDE3- og PDE4-inhiberende aktivitet
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
PT1147087E (pt) Feantridina-n-oxidos com actividade de inibicao de pde-iv
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
SI1147088T1 (sl) 6-arilfenantridini s PDE-IV inhibirajoco aktivnostjo
AU758194C (en) Novel benzimidazoles and benzoxazoles